Assessment of hearing dysfunction in patients with Graves' disease and thyroid eye disease without or with teprotumumab.

Terry J SmithRobert J HoltQianhong FuAnahita QashqaiNaina BarrettoElizabeth ConradJason A Brant

Published in: The Journal of clinical endocrinology and metabolism (2024)

These analyses indicate similar occurrence of hearing claims in patients with GD/TED alone as following teprotumumab treatment. Future analyses of incremental hearing risk from teprotumumab should utilize a priori study designs accounting for background hearing dysfunction in patients with GD/TED.

Keyphrases

hearing loss
oxidative stress
risk assessment
health insurance
current status
combination therapy
clinical evaluation